Innovent Biologics Ends Proposed Subscription Agreement
Company Announcements

Innovent Biologics Ends Proposed Subscription Agreement

Innovent Biologics (HK:1801) has released an update.

Innovent Biologics has decided to terminate its proposed subscription agreement with Fortvita and Lostrancos after receiving feedback from shareholders. The company remains committed to its strategic objectives and aims to focus on long-term international growth, believing that the termination is in the best interest of shareholders.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Reports Strong Revenue Growth in Q3 2024
TheFlyInnovent Biologics says picankibart phase 2 study met primary endpoint
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App